Share：
Share this content in WeChat
X
[Chinese][PDF]133292
• Clinlcal Guidelines & Expert Consensu •
Clinical application and controversy of imaging for myocardial viability-the interpretation of a consensus statement of the American Heart Association
DONG Zhixiang  ZHAO Shihua 

Cite this article as: Dong ZX, Zhao SH. Clinical application and controversy of imaging for myocardial viability-the interpretation of a consensus statement of the American Heart Association[J]. Chin J Magn Reson Imaging, 2021, 12(4): 75-77. DOI:10.12015/issn.1674-8034.2021.04.016.


[Abstract] There are a large amount of patients with ischemic left ventricular dysfunction who get poor prognosis, but appropriate revascularization can significantly improve the survival rate and the quality of life of these patients. Using different indicators reflecting myocardial activity, there are numerous available imaging technologies for viable myocardial detection. Most previous retrospective analyses thought that there was a clear correlation between viable myocardium and the benefits of revascularization, but recent large-scale prospective clinical trials have failed to prove that, making the clinical application of imaging for myocardial viability faces new challenges. Based on the latest consensus statement of the American Heart Association on imaging for myocardial viability in 2020, this article summarizes the commonly used imaging techniques for myocardial viability detection and clinical application protocol, and further analyzes the controversy arising from recent clinical trials and future research directions.
[Keywords] ischemic heart disease；imaging for myocardial viability；revascularization；magnetic resonance imaging；American Heart Association

DONG Zhixiang   ZHAO Shihua*  

MR Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases of China, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China

Zhao SH, E-mail: cjr.zhaoshihua@vip.163.com

Conflicts of interest   None.

This work was part of National Natural Science Foundation of China (No. 81930044, 81620108015).
Received  2021-01-04
Accepted  2021-01-29
DOI: 10.12015/issn.1674-8034.2021.04.016
Cite this article as: Dong ZX, Zhao SH. Clinical application and controversy of imaging for myocardial viability-the interpretation of a consensus statement of the American Heart Association[J]. Chin J Magn Reson Imaging, 2021, 12(4): 75-77. DOI:10.12015/issn.1674-8034.2021.04.016.

1
Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: A report from the American heart association[J]. Circulation, 2019, 139(10): e56-e528. DOI: 10.1161/cir.0000000000000659.
2
Garcia MJ, Kwong RY, Scherrer-Crosbie M, et al. State of the Art: Imaging for Myocardial Viability: A Scientific Statement From the American Heart Association[J]. Circ Cardiovasc Imaging, 2020, 13(7): e000053. DOI: 10.1161/HCI.0000000000000053.
3
Shah DJ, Kim HW, James O, et al. Prevalence of regional myocardial thinning and relationship with myocardial scarring in patients with coronary artery disease[J]. JAMA, 2013, 309(9): 909-918. DOI: 10.1001/jama.2013.1381.
4
Schmidt M, Voth E, Schneider CA, et al. F-18-FDG uptake is a reliable predictory of functional recovery of akinetic but viable infarct regions as defined by magnetic resonance imaging before and after revascularization[J]. Magn Reson Imaging, 2004, 22(2): 229-236. DOI: 10.1016/j.mri.2003.07.006.
5
Dilsizian V, Rocco TP, Freedman NM, et al. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging[J]. N Engl J Med, 1990, 323(3): 141-146. DOI: 10.1056/nejm199007193230301.
6
Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures[J]. J Nucl Cardiol, 2016, 23(5): 1187-1226. DOI: 10.1007/s12350-016-0522-3.
7
Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction[J]. N Engl J Med, 2000, 343(20): 1445-1453. DOI: 10.1056/nejm200011163432003.
8
Kellman P, Xue H, Olivieri LJ, et al. Dark blood late enhancement imaging[J]. J Cardiovasc Magn Reson, 2016, 18(1): 77. DOI: 10.1186/s12968-016-0297-3.
9
Jamiel A, Ebid M, Ahmed AM, et al. The role of myocardial viability in contemporary cardiac practice[J]. Heart Fail Rev, 2017, 22(4): 401-413. DOI: 10.1007/s10741-017-9626-3.
10
Panza JA, Ellis AM, Al-Khalidi HR, et al. Myocardial viability and long-term outcomes in ischemic cardiomyopathy[J]. N Engl J Med, 2019, 381(8): 739-748. DOI: 10.1056/NEJMoa1807365.
11
Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2)[J]. J Am Coll Cardiol, 2007, 50(20): 2002-2012. DOI: 10.1016/j.jacc.2007.09.006.
12
Orlandini A, Castellana N, Pascual A, et al. Myocardial viability for decision-making concerning revascularization in patients with left ventricular dysfunction and coronary artery disease: a meta-analysis of non-randomized and randomized studies[J]. Int J Cardiol, 2015, 182: 494-499. DOI: 10.1016/j.ijcard.2015.01.025.

PREV Differential diagnosis value of MRI image texture analysis for uterine fibroid and adenomyosis
NEXT Large B cell lymphoblastic lymphoma of the scalp in children: A case report
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn